Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : MCRR Refugees -- Ignore unavailable to you. Want to Upgrade?

To: WallStBum who wrote (57)	7/6/1998 11:20:00 AM
From: caly	Read Replies (1) \| Respond to of 582

Sorry Dax, not in it and haven't looked at it. Wish I had gotten in a while ago though. I thought I remembered some of you guys kicking it around though, so that's why I mentioned it.

To: WallStBum who wrote (57)	7/6/1998 1:38:00 PM
From: Claudia Benson	Read Replies (3) \| Respond to of 582

Dax, I don't have historical pricing, but it was ~ 60 cents last week. Here's today's news release. This was never mentioned on the MCRR board. Got the original information back in Sept, from WAACO. That 2 dollar word created all the whoopla today. ;-) Check out the CYGS thread, you'll get some realistic information, w/o the usual hype. Maybe Dr Epstein will give us his take on this. Claudia...ps What is the difference between "in vivo" and "in vitro"? CSI Researchers Express ssDNA in Vivo HOUSTON--(BW HealthWire)--July 6, 1998--Cryogenic Solutions Inc. (OTC BB:CYGS - news) announced the expression of sequence specific oligodeoxyribonucleotides from a ribonucleic acid expression vector. This in vivo expression of single-stranded DNA (ssDNA) that is complementary to an RNA template encoded in a vector was accomplished under a sponsored research agreement by CSI. The option of having flanking regions present or absent in the expressed ssDNA product is an additional useful property of this work. CSI holds the patent rights of this and related technology developed under the sponsored research agreement. This press release contains no forward looking statements and is therefore in no need of protection under the Securities Litigation Reform Act of 1995. Investment in the securities of the company is imprudent and not recommended if the press release as written is not clearly understood by the investor. Background information available on the website <www.biogenix.com> email -- cygs@wt.net For additional information please call 713/780-1399, 9-4 CST Investor relations -- Dell Gibson, VP Biotech details -- Craig Tomlinson, PhD